Re-Vana Therapeutics Raises USD11.9M in Series A Funding
Summary
Re-Vana Therapeutics Ltd, a Belfast, Northern Ireland, UK-based specialty drug delivery company developing sustained-release therapeutics for the treatment of vision-threatening ocular diseases, closed its Series A round with $11.9m in funding. In conjunction with this financing, Re-Vana’s board of directors has been further strengthened by the appointments of Robert Avery, M.D., of Visionary Ventures and InFocus Capital Partners, as board member, and Michael O’Rourke, President and CEO of Re-Vana Therapeutics, as Board Chair. Founded in 2016 as a spin-out from Queen’s University Belfast, Northern Ireland, Re-Vana Therapeutics is a specialty ocular therapeutic and drug delivery company with headquarters located in Belfast and a U.S.-based office, Re-Vana Therapeutics, Inc., in Tampa, Florida. it is currently developing sustained release ophthalmic therapeutics aimed at reducing the frequency of intravitreal injections required to treat a wide range of retinal diseases, including neovascular age-related macular degeneration (wet AMD). In addition, its proprietary photo-crosslinked sustained-release technology may enable the development of a broad range of novel, sustained release products applicable to a variety of therapeutic areas.